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Abstract
Mutation screening of the breast cancer genes BRCA1 and BRCA2 identifies a large fraction
of variants of uncertain clinical significance (VUS) whose functional and clinical interpreta-
tions pose a challenge for genomic medicine. Likewise, an increasing amount of evidence
indicates that genetic variants can have deleterious effects on pre-mRNA splicing. Our goal
was to investigate the impact on splicing of a set of reported variants of BRCA2 exons 17
and 18 to assess their role in hereditary breast cancer and to identify critical regulatory ele-
ments that may constitute hotspots for spliceogenic variants. A splicing reporter minigene
with BRCA2 exons 14 to-20 (MGBR2_ex14-20) was constructed in the pSAD vector. Fifty-
two candidate variants were selected with splicing prediction programs, introduced in
MGBR2_ex14-20 by site-directed mutagenesis and assayed in triplicate in MCF-7 cells.
Wild type MGBR2_ex14-20 produced a stable transcript of the expected size (1,806 nucleo-
tides) and structure (V1-[BRCA2_exons_14–20]–V2). Functional mapping by microdele-
tions revealed essential sequences for exon recognition on the 3’ end of exon 17 (c.7944-
7973) and the 5’ end of exon 18 (c.7979-7988, c.7999-8013). Thirty out of the 52 selected
variants induced anomalous splicing in minigene assays with >16 different aberrant tran-
scripts, where exon skipping was the most common event. A wide range of splicing motifs
were affected including the canonical splice sites (15 variants), novel alternative sites (3 var-
iants), the polypyrimidine tract (3 variants) and enhancers/silencers (9 variants). According
to the guidelines of the American College of Medical Genetics and Genomics (ACMG), 20
variants could be classified as pathogenic (c.7806-2A>G, c.7806-1G>A, c.7806-1G>T,
c.7806-1_7806-2dup, c.7976+1G>A, c.7977-3_7978del, c.7977-2A>T, c.7977-1G>T,
c.7977-1G>C, c.8009C>A, c.8331+1G>T and c.8331+2T>C) or likely pathogenic (c.7806-
9T>G, c.7976G>C, c.7976G>A, c.7977-7C>G, c.7985C>G, c.8023A>G, c.8035G>T and
c.8331G>A), accounting for 30.8% of all pathogenic/likely pathogenic variants of exons 17–
18 at the BRCA Share database. The remaining 8 variants (c.7975A>G, c.7977-6T>G,
c.7988A>T, c.7992T>A, c.8007A>G, c.8009C>T, c.8009C>G, and c.8072C>T) induced
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partial splicing anomalies with important ratios of the full-length transcript (70%), so that
they remained classified as VUS. Aberrant splicing is therefore especially prevalent in
BRCA2 exons 17 and 18 due to the presence of active ESEs involved in exon recognition.
Splicing functional assays with minigenes are a valuable strategy for the initial characteriza-
tion of the splicing outcomes and the subsequent clinical interpretation of variants of any dis-
ease-gene, although these results should be checked, whenever possible, against patient
RNA.
Author summary
A significant proportion of disease-causing mutations of inherited disorders impair splic-
ing. Massive sequencing projects of genetic diseases generate thousands of sequence varia-
tions that require functional and clinical interpretations. We have shown that splicing
reporter minigenes of the breast cancer genes BRCA1 and BRCA2 are useful tools to func-
tionally test DNA variants. In this work, we have constructed a 7-exon BRCA2 minigene
(exons 14 to 20) where we mapped critical splicing regulatory sequences and tested 52
selected variants of exons 17 and 18 detected in breast cancer patients. We finely located
three DNA segments on both exons that presumably contain splicing enhancer sequences.
We observed that a total of 30 variants of any type disrupted the splicing patterns and,
given the severity of their outcomes, we classified 20 of them as pathogenic or likely patho-
genic. We also showed that a wide range of splicing elements were affected including
canonical and novel 5’ and 3’ splice sites, the polypyrimidine tract and enhancer and
silencer sequences. We concluded that splicing aberrations are frequent in Hereditary
Breast and Ovarian Cancer and that minigenes are valuable tools to functionally classify
DNA variants of any human disease gene under the splicing viewpoint.
Introduction
Germline pathogenic variants in the tumor suppressor genes BRCA1 (MIM# 113705) and
BRCA2 (MIM# 600185) are associated with increased risk of breast and ovarian cancer [1,2],
and account for about 16% of the familial risk for breast cancer [3]. More than 25 breast cancer
susceptibility genes have been identified so far, most of which play a role in the DNA repair
pathway linked to BRCA1 and BRCA2 [4]. Additionally, a vast number of SNPs have been
associated with breast cancer risk [5,6], increasing the complexity of the genetic landscape of
Hereditary Breast/Ovarian Cancer (HBOC). Moreover, according to the BRCA Share Data-
base (http://www.umd.be/BRCA2/; last accessed date, April 2016), more than 2700 different
sequence variations have been reported at the BRCA2 gene, ~30% of which are causal. A large
proportion of the recorded pathogenic variants truncate the BRCA2 protein (nonsense and
frameshift). However, up to 20% of BRCA1/2 tests report variants of uncertain clinical signifi-
cance (VUS) [7]. These pose a challenge in genetic counselling as VUS-carrier families are usu-
ally considered as negative (undetermined) so they cannot benefit from prevention protocols
[8].
In fact, other factors must be involved in the pathogenesis of genetic disorders since gene
expression is regulated by a wide range of cis-regulatory sequences that control it, as for exam-
ple, transcription initiation (promoter) [9], pre-mRNA splicing [10] or post-transcriptional
regulation and mRNA stability (3’UTR) [11]. It is therefore expected that point mutations in
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those motifs can be correlated with gene expression alterations and disease. Interestingly,
nearly 90% of disease-associated SNPs are placed outside protein-coding regions (45% intro-
nic, 43% intergenic), suggesting a relevant role of the non-coding sequence variations [12].
Splicing is a central process of gene expression whereby introns are excised and exons are
joined sequentially. It has been calculated that>90% of mammalian genes undergo alternative
splicing which is controlled by a dense array of diverse cis-acting elements and splicing factors
[10,13]. According to GENCODE (V.24, http://www.gencodegenes.org/stats/current.html),
the average number of protein coding transcripts per gene is ~4. In this regard, it has been
recently reported the existence of 24 naturally occurring alternative splicing events of the
BRCA2 gene [14]. Alternative splicing not only allows transcriptome and proteome diversity,
but it also regulates important processes such as embryonic development or cell differentia-
tion. Exon recognition requires specific signals at the 5’ and 3’ splice sites, the polypyrimidine
tract, the branch point, and supplementary sequences referred to as Exonic Splicing Enhancers
(ESE) and Silencers (ESS) [15]. Interestingly, an unexpectedly large fraction of variants can
actually disrupt pre-mRNA processing [16,17]. Remarkably, aberrant splicing is common in
cancer so that it can be considered a hallmark of this disease [18]. We previously estimated
that a significant proportion of likely pathogenic BRCA1/2 variants (33.9%) from 14 exons
would impair splicing [19].
The most suitable method to identify splicing aberrations is based on the study of patient
RNA of the affected tissue although this sort of sample is not always available [20,21]. Never-
theless, direct RNA analysis of several disease genes, including NF1 (MIM# 613113) and
BRCA1/2, has proven to be a highly sensitive method to identify splicing anomalies [22,23].
Minigene-based technologies have become alternative approaches to primarily test whether a
specific DNA variant affects splicing, especially when patient samples cannot be collected. In a
recent report we presented the new splicing reporter plasmid pSAD (Patent P201231427-
CSIC) that constituted the backbone of the largest BRCA2 minigene ever reported with 9
exons (19 to 27) [24]. This construct allowed the analysis of 40 variants spread throughout
these exons and flanking introns, demonstrating its capability for the successful identification
and characterization of spliceogenic variants. Moreover, up to date, we have examined the
impact on splicing of 112 different DNA variants by minigene assays, 51 of which induced
aberrant splicing patterns [19,24,25].
The intronic GT dinucleotide in positions +1 and +2 is the most conserved element of the
donor splice signal. However, in a small fraction of the donor sites (<1%), GT is replaced by
GC that are rather located in alternatively spliced introns [26,27]. Recognition of a GC donor
site at the BTK gene was associated with splicing enhancers for SR proteins 9G8, Tra2β and
SC35 [27]. The BRCA2 intron 17 has also a 5’ GC motif and there have been identified minor
natural alternative splicing isoforms Δ18 (exon 18 skipping) and Δ17,18 (exons 17+18 skip-
ping) [14,28]. To study the regulatory mechanisms of both exons and how DNA variants
affect this process we constructed a large minigene with exons 14 to 20 in the pSAD plasmid
(MGBR2_ex14-20) to keep the genomic context. Splicing regulatory elements were searched
by functional microdeletion mapping. Finally, 52 variants detected in HBOC patients were
selected and assayed in the minigene MGBR2_ex14-20.
Results
The minigene MGBR2_ex14-20 (10,734 bp) was built as indicated in materials and methods.
The insert (5,837 bp) corresponds to a genomic region of 16,762 bp of the BRCA2 gene (Fig
1A). To validate it, we transfected the final (14–20) and the intermediate constructs (17–18,
16–18 and 16–20) into MCF-7 cells, we isolated the RNA and performed the RT-PCR with
Functional classification of BRCA2 DNA variants by minigene assays
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specific primers at the vector-exons. Fig 1B shows the transcripts generated by the pSAD
vector, two intermediate (16–18 and 16–20) and the final constructs of this minigene.
MGBR2_ex14-20 produced a full-length transcript of the expected size (1,806 nucleotides—
nt-) and structure (V1-BRCA2 exons 14 to 20-V2) without any anomalies, so this minigene
was ready for regulatory studies and variant analysis. The switch of the GC site of exon 17 to a
strong canonical GT site (artificial variant c.7976+2C>T; NNSplice = 1.0) rendered the same
canonical transcript without any anomalies (9 independent assays), like the GC counterpart
(S1 Fig), that was confirmed by sequencing. Finally, exons 12 and 13 were also cloned in two
independent stages but splicing reactions did not produce the expected canonical transcripts
so they were ruled out.
Mapping of exonic and intronic splicing regulatory sequences
The efficient inclusion of the exons in the mature mRNA may require the presence of
enhancer sequences and the binding to SR-proteins [29]. The highest density of active ESEs is
near splice sites (~50 nt at both exon ends) with a maximum between 10 and 20 nucleotides
from the canonical 5’ and 3’ splice sites of each exon [30]; so DNA variants at these regions
have a higher likelihood of disrupting ESEs. Furthermore, previous studies suggested a specific
regulation of the donor GC-sites by ESEs [27]. We therefore proceeded to map regulatory
sequences involved in exons 17 and 18 processing by functional tests of four exonic 30-nt dele-
tions of each exon. These deletions covered the 5’ and 3’ 55 nucleotides of each exon excluding
the first two and last three nucleotides. Three 30-nt microdeletions, c.7944_7973del (exon 17),
Fig 1. Structure and functional analysis of the minigene MGBR2_ex14-20. A) Structure of the minigene
MGBR2_ex14-20 (slashes indicate shortened introns): [IVS14 (328 pb)–EX14 (428 pb)–IVS14 (1139 pb)—
EX15 (182 pb)–IVS15 (358 pb) // IVS15 (333 pb)–EX16 (188 pb)–IVS16 (234 pb) // IVS16 (181 pb)–EX17 (171
pb)–IVS17 (485 pb)–EX18 (355 pb)–IVS18 (314 pb) // IVS18 (235 pb)–EX19 (156 pb)–IVS19 (398 pb)–EX20
(145 pb)–IVS20 (207 pb)]. Boxes highlight the 4 different cloning steps of this minigene. The expected splicing
reactions in eukaryotic cells are indicated by arrows. B) Splicing functional analysis of the empty vector pSAD
and the final (14–20) and intermediate (16–18, 16–20) constructs in MCF-7 cells. The four electropherograms
were overlaid. cDNAs were amplified with vector exon specific primers SD6-PSPL3_RTFW and RTpSAD-RV
(arrows within vector exons V1 and V2 above). Full-length transcripts are shown as blue peaks and the
Genescan Liz-1200 size standard is shown as orange/faint peaks. Fragment sizes (bp) and relative fluorescent
units are indicated on the x- and y-axes, respectively.
https://doi.org/10.1371/journal.pgen.1006691.g001
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c.7979_8008del (exon 18) and c.8004_8033del (exon 18), had impacts on splicing (exon 17 or
18 skipping) (Fig 2A), indicating that these sequences probably contain regulatory motifs guid-
ing exon recognition. According to the ESEfinder algorithm [31], these sequences contain
several putative enhancer sequences (see Fig 2C), but only SF2/ASF and SRp40 motifs were
present in the three deletions suggesting that these SR proteins might be required for compe-
tent exon identification. We then carried out the fine mapping of ESEs with additional
internal 10-nt deletions of exons 17 [c.7944_7953del (del1), c.7954_7963del (del2) and
c.7964_7973del (del3)] and 18 [c.7979_7988del (del4), c7989_7998del (del5), c.7999_8008del
(del6), c.8004_8013del (del7; 5-nt overlap between del6 and del7), c.8014_8023del (del8) and
c.8024_8033del (del9)] (S2 Table; Fig 2B). The del2 and del3 deletions of exon 17 only dis-
rupted splicing weakly (2.2% and 4.6% of aberrant transcripts, respectively; S3 Table) whereas
del1 did not at all. Exon 18 skipping was found at del4, del6 and del7. These segments must
therefore contain splicing enhancer sequences. Deletions 5, 8 and 9 of exon 18 did not affect
splicing and produced the expected transcripts.
According to the bioinformatics predictions of ESEs (Fig 2C), the common feature of the
three positive exon 18 deletions was the presence of two putative ESEs for SF2/ASF (one in the
overlapping segment of del6-7) at nucleotides c.7981_7987 (GATACGG) and c.8001_c.8007
(CAGAAGA). We then proceeded to disrupt both motifs by mutagenesis with the following
sequence variations: c.7984A>T, c.8001C>T and c.8003G>A, which target conserved nucleo-
tides of the two SF2 motifs (Fig 2C, S2 Table) [31]. We carried out the assays with the triple
mutant, a double mutant c.[8001C>T;8003G>A], which targeted the SF2-II site, and the three
independent variants (Fig 2B and 2C). Intriguingly, only the triple and the double mutants
remarkably impaired splicing with 59.7% and 44.2% of aberrant transcripts (Fig 2B), respec-
tively, but these effects were not observed either with c.7984A>T or c.8001C>T, which did
not apparently affect splicing, whereas c.8003G>A only induced weak exon 18 skipping
(8.8%), suggesting a synergistic effect of these variants on splicing. We can conclude that these
sequences are required for exon 18 recognition so that any variation in these nucleotides may
affect splicing and confer breast cancer risk. In order to investigate the participation of SF2/
ASF in this process, we initially performed inhibition experiments with siRNAs of splicing fac-
tors SF2/ASF, SC35 and Tra2β. Preliminary data unexpectedly suggested a role for SC35 in
exons 17 and 18 definitions as well as small contributions of Tra2β and SF2/ASF (S2 Fig). In
fact, a putative SC35 motif (GGCTATAA, c.8010-8017) was located at the spliceogenic del7
deletion (Fig 2C).
We also searched for ESE sequences within intron 17. Firstly, we selected a region of 115
nucleotides (c.7976+231_7977-141del) where Human Splicing Finder (HSF) had predicted the
presence of a notable concentration of high-scored Tra2β sites (S2 Table), being Tra2β one of
the SR-proteins involved in GC recognition in the BTK gene [27]. The presence of SREs was
also checked in the rest of the intron 17 with another three deletions, c.7976+21_7976+140del,
c.7976+136_7976+240del and c.7977-150_7977-21del. However, none of them had an impact
on splicing suggesting that regulatory elements of the GC site are not located within intron 17.
Identification of spliceogenic variants
A total of 221 reported DNA variants (BRCA Share, BIC and 1000 Genomes databases, last
accessed date: April 2016) were analyzed with NNSPLICE and HSF. We selected fifty-four out
of them (24.4%) on basis of these criteria: splice site disruption or modification, creation of
alternative splice sites, disruption of an ESE within positive 30-nt microdeletions, creation of
silencers (specifically hnRNPA1 sites) (S2 Table). Remarkably, 36 variants had previously been
classified as VUS by the BRCA Share and BIC databases. All the selected DNA changes were
Functional classification of BRCA2 DNA variants by minigene assays
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Fig 2. Map of splicing enhancers for recognition of exons 17 and 18. A) Functional mapping of ESEs of
exons 17 (left) and 18 (right) by exonic microdeletions (30-nt above) of the wild type minigene MGBR2_ex14-
20. cDNA was amplified with primers of BRCA2 exon 16 (RTBR2_ex16-FW) and vector exon V2
(RTpSAD-RV; amplicon size = 1012 nt) and run in 1.5% agarose gel. Arrows indicate abnormal transcripts. B)
Functional analysis of 10-nt microdeletions of exon 18 (left) and single nucleotide substitutions (right)
c.7984A>T that disrupts SF2-I, and c.8001C>T and 8003G>A that target SF-II motif (see ESE map below).
The triple mutant is the combination c.[7984A>T;8001C>T;8003G>A], and the double one is c.
[8001C>T;8003G>A]. C) HSF predictions of putative ESE motifs of exon 17 (above) between cDNA positions
7944 and 7973 and exon 18 (below) between cDNA positions 7979–8008 and 8004–8033. Intronic
sequences are in lower case. SF2*motif of exon 17 is detected by the specific SF2/ASF (IgM-BRCA1)
algorithm of ESEfinder. Red and pink microdeletions alter splicing. Artificial SF2- single-nucleotide
substitutions are indicated above exon 18 sequence.
https://doi.org/10.1371/journal.pgen.1006691.g002
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introduced into the wild type MGBR2_ex14-20 construct by site-directed mutagenesis except
for two (c.7829dup—exon17- and c.8169_8172dup—exon18-) that were disregarded because
of the recurrent failure of the mutagenesis experiments.
Fifty-two variants (17 of exon 17 and 35 of exon 18) were functionally tested in the splicing
reporter minigene MGBR2_ex14-20. All the transcripts were quantified to evaluate their possi-
ble implication in disease pathogenesis (S3 Table). Only variants with5% of anomalous tran-
scripts were considered as positive. Thirty DNA variants (57.7%) impaired splicing (Table 1,
S3 Table, Figs 3 and 4, S3 Fig), whilst another three variants (c.7875A>G, c.7985C>T and
c.8042C>G) had weak impacts on splicing (4.7%, 3.3% and 2.3%, respectively; S3 Table). All
the splicing outcomes were highly reproducible with low intra-variability (standard deviations
<1.8% for 27 variants; S3 Table). Spliceogenic variants consisted of 14 intronic and 16 exonic
variants that had previously been predicted as 11 missense, 1 nonsense, 1 frameshift and 3 syn-
onymous variants, confirming that any type of genetic variant can potentially disrupt pre-
mRNA processing.
According to the prediction software and their location,15 variants disrupted the canonical
3’ and 5’ splice sites (c.7806-2A>G, c.7806-1G>A, c.7806-1G>T, c.7806-1_7806-2dup—previ-
ously reported as c.7806insAG-, c.7975A>G, c.7976G>C, c.7976G>A, c.7976+1G>A, c.7977-
3_7978del, c.7977-2A>T, c.7977-1G>T, c.7977-1G>C, c.8331G>A, c.8331+1G>T and
c.8331+2T>C), three disrupted the polypyrimidine tract (c.7806-9T>G, c.7977-7C>G
and c.7977-6T>G), three created novel active splice sites (c.8023A>G, c.8035G>T and
c.8168A>G, but also c.7977-7C>G and c.7806-1_7806-2dup—see above-), seven affected
enhancer or silencer motifs (c.7992T>A, c.8007A>G, c.8009C>A, c.8009C>T, c.8009C>G,
c.8072C>T and c.8249_8250del, all of them in exon 18) and two were presumed to alter ESE/
ESS motifs and generate alternative sites (c.7985C>G—weak 3’ss- and c.7988A>T—strong
5’ss-) that actually were not used, so they should be considered as ESE/ESS-variants. Seven
of the ESE/ESS variants were placed into the positive ESE-containing microdeletions
c.7979_8008del30 and c.8004_8033del30, spanning a 25-nt interval of exon 18 (c.7985-8009).
Characterization of aberrant transcripts
Variants of exon 17 and flanking intronic sequences rendered 6 different abnormal transcripts
(Fig 5): ex17 skipping, ex17-ins8 (alternative intronic acceptor 8 nt upstream), ex17-del1
(novel acceptor 1 nt downstream), ex17-del20 (alternative acceptor 20 nt downstream),
ex17-del69 (alternative acceptor 69 nt downstream) and ex17-insAG (novel acceptor 2 nt
upstream), where exon 17 skipping was the most abundant event. Mutations at exon 18 and
contiguous sequences induced more than 10 different aberrant transcripts (Fig 5): ex18 skip-
ping, ex18-ins6 (novel intronic acceptor 6 nt upstream), ex18-del191 (alternative acceptor 191
nt downstream), ex18-del309 (new donor 309 nt upstream), ex18-del298 (new donor 298 nt
upstream), ex18-del164 (new donor 164 nt upstream), ex18-del157 (use of cryptic donor 157
nt upstream), and rare phenomena such as ex17-del20+ex18 skipping (cryptic acceptor plus
skipping), ivs17_58 nt retention+ex18 skipping (intronic cryptic donor plus skipping), one
878-nt transcript as well as other uncharacterized aberrant transcripts. Exon 18 skipping was
the most frequent outcome (19 out of 21 variants induced it). Twelve transcripts would intro-
duce premature termination codons (PTC).
Discussion
The functional and clinical classifications of DNA variants of breast cancer genes provide
essential information for clinical management of patients and asymptomatic carriers. The
identification of VUS in patients hampers the genetic counseling of BC families since the result
Functional classification of BRCA2 DNA variants by minigene assays
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Table 1. Splicing outcomes of BRCA2 exons 17 and 18 variants.
DNA variant 1 Motif 2 Splicing outcome3 RNA effect4 Protein Effect4
c.7806-9T>G Pyr Ex17 skipping (41.5%); Ivs16-ins8
(36.3%); Ex17-del69 (22.2%)
r.[7806_7976del,7805_7806ins7806-8_7806–
1,7806_7874del]
p. [A2603_R2659del;
R2602Sfs*49;
A2603_R2625del]
c.7806-2A>G [-] 3’SS Ex17-del20 (51.8%); Ex17-del69
(28.1%); Ex17 skipping (20.1%)
r.[7806_7825del,7806_7874del,7806_7976del] p.[A2603Cfs*8;
A2603_R2625del;
A2603_R2659del]
c.7806-1G>A [-] 3’SS Ex17-del1 (100%) r.[7806_7807del] p.A2603Lfs*45
c.7806-1G>T [-] 3’SS Ex17-del20 (100%) r.7806_7825del p.A2603Cfs*8
c.7806-1_7806-
2dup
[+]3’SS Ex17-insAG (92.6%); Ex17 skipping
(5.1%); Ex17-del69 (2.3%)
r.[7805_7806insAG,7806_7976del,7806_7874del] p. [A2603Gfs*46;
A2603_R2659del;
A2603_R2625del]
c.7975A>G [-] 5’SS CT (73.8%); Ex17 skipping (26.2%) r.[7975a>g,7806_7976del] p. [R2659G;
A2603_R2659del]
c.7976G>C [-] 5’SS Ex17 skipping (100%) r.7806_7976del p.A2603_R2659del
c.7976G>A [-] 5’SS Ex17 skipping (100%) r.7806_7976del p.A2603_R2659del
c.7976+1G>A [-] 5’SS Ex17 skipping (100%) r.7806_7976del p.A2603_R2659del
c.7977-7C>G [+]
3’SS/
Pyr
Ex18-ins6 (78.4%); exon 18 skipping
(21.6%)
r.[7976_7977ins6,7977_8331del] p.[Y2658_R2659insSF;
Y2660Ffs*43]
c.7977-6T>G Pyr CT (66.7%); Ex18 skipping (31%);
ex18-del191 (2.3%)
r. [=, 7977_8331del,7977_8167del] p. [=; Y2660Ffs*43;
Y2660Wfs*6]
c.7977-
3_7978del
[-] 3’SS Ex18 skipping (90%) ex18-del191
(10%)
r.[7977_8331del,7977_8167del] p.[Y2660Ffs*43;
Y2660Wfs*6]
c.7977-2A>T [-] 3’SS Ex18 skipping (93.3%); ex18-del191
(6.7%)
r.[7977_8331del,7977_8167del] p.[Y2660Ffs*43;
Y2660Wfs*6]
c.7977-1G>T [-] 3’SS Ex18 skipping (91.5%); ex18-del191
(7%); ex18-del236 (1.5%)
r.[7977_8331del,7977_8167del,7977_8212del] p.[Y2660Ffs*43;
Y2660Wfs*6;R2659Sfs*26]
c.7977-1G>C [-] 3’SS Ex18 skipping (89.8%); Ex18-del191
(10.2%)
r.[7977_8331del,7977_8167del,?] p.[Y2660Ffs*43;
Y2660Wfs*6;?]
c.7985C>G [-]ESE/
[+]ESS
Ex18 skipping (90.2%); Ex18-del191
(5%); others (4.8%)
r.[7977_8331del,7977_8167del,?] p.[Y2660Ffs*43;
Y2660Wfs*6;?]
c.7988A>T [+]5’SS
[-]ESE
CT (84.2%); Ex18 skipping (8.6%)
+ others (7.2%)
r.[7988a>u,7977_8331del,?] p.[E2663V;Y2660Ffs*43;?]
c.7992T>A [-]ESE/
[+]ESS
CT (68.6%); ex18 skipping (31.4%) r.[7992u>a,7977_8331del] p. [=; Y2660Ffs*43]
c.8007A>G [-]ESE/
[+]ESS
CT (84.8%); ex18 skipping (15.2%) r.[8007a>g,7977_8331del] p. [=; Y2660Ffs*43]
c.8009C>A [-]ESE/
[+]ESS
Ex18 skipping (91.2%); Ex18-del191
(4.8%); CT (4%)
r.[7977_8331del,7977_8167del,8009c>a,?] p. [Y2660Ffs*43;
Y2660Wfs*6;S2670*;?]
c.8009C>T [-]ESE/
[+]ESS
CT (76.6%); ex18 skipping (23.4%) r.[8009c>u,7977_8331del] p.[S2670L;Y2660Ffs*43]
c.8009C>G [-]ESE/
[+]ESS
CT (79.9%); ex18 skipping (20.1%) r.[8009c>g,7977_8331del] p.[S2670W;Y2660Ffs*43]
c.8023A>G [+]5’SS Ex18-del309 (93%); other aberrant
transcripts (7%)
r.[8023_8331del,?] p.[Ile2675_K2777del;?]
c.8035G>T [+]5’SS Ex18-del298 (93.6%); 878-nt
transcript (4%); CT: 2.4%
r.[8034_8331del,?] p.[D2679Ffs*43;?]
c.8072C>T [-]ESE/
[±]ESS
CT (94.9%); ex18 skipping (5.1%) r.[8072c>u,7977_8331del] p.[S2691F;Y2660Ffs*43]
c.8168A>G [+]5’SS CT (69.6%); Ex18-del164 (25.9%)
/Ex18 skipping (4.5%)
r.[8168a>g,8168_8331del,7977_8331del] p.[D2723G;G2724Ffs*3;
Y2660Ffs*43]
c.8249_8250del [-]ESE/
[-]ESS
CT (93.0%); ex18 skipping (7.0%) r.[8249_8250del,7977_8331del] p.[K2750Asnfs*13;
Y2660Ffs*43]
(Continued )
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of the genetic test is ambiguous. Pathogenicity of genetic alterations is usually assumed for
sequence variants that introduce PTCs, such as frameshift and nonsense mutations, or some
missense changes that disrupt protein function. However, many other DNA variants can
affect disease risk as other mechanisms of gene expression, such as pre-mRNA processing, are
affected. In fact, many germ-line variants of human disease genes have already been associated
with aberrantly spliced mRNAs that encode defective proteins [32].
In this work, we have carried out one of the most comprehensive studies of the correlation
between aberrant splicing and breast cancer, whereby we evaluated the impact on splicing
of 52 DNA variants of BRCA2 exons 17 and 18 with the stable seven-exon minigene
MGBR2_ex14-20. We have shown that spliceogenic variants are relatively abundant in exons
17 and 18 (30/52 tests), representing ~15% of all reported variants of these exons and flanking
intronic sequences. This rate triplicates the frequency of splice sites variants (<10 bp from
exon) at the BRCA Share database (131/2818 recorded variants, 4.6%). Remarkably, these 30
variants were found in 157 different records of the BIC and BRCA Share databases. A high
prevalence of spliceogenic variants has been reported in several disease genes, such as NF1,
where up to 44% of patients carry such type of alterations [23,33]. So far we have performed
lymphocyte or minigene RNA assays of 188 variants, 93 of which (49.5%) disrupted splicing
[19,24,25].
We have once more demonstrated the high capacity, robustness and simplicity of splicing
reporter minigenes, with the following advantages: a) observation of a single-mutant allele
effect without the interference of the wild type counterpart in patient samples; b) precise quan-
tification of all anomalous transcripts by inhibiting the NMD; c) high capacity of this simple
technical approach (Cloning-Mutagenesis-Functional Assay) [19,24,25,28,34]; d) one single
minigene-construct allows the analysis of multiple variants from different exons (seven exons
in this case); e) high reproducibility of physiological/pathological splicing patterns by virtue of
keeping the genomic context of each exon. This was supported by comparing our results with
previous studies based on patient RNA data. We found at previous reports that 8 DNA variants
under study yielded, all of them, the same or similar results for patient RNA and minigene
assay. Thus, DNA variants: c.7806-9T>G (exon 17 skipping+ex17-del69+ivs16-ins8) [35],
c.7975A>G (partial exon 17 skipping) [36], c.7976G>A and c.7976G>C (total exon 17
skipping) [37,38], c.7988A>T (partial exon 18 skipping) [38], c.7992A>T (partial exon 18
Table 1. (Continued)
DNA variant 1 Motif 2 Splicing outcome3 RNA effect4 Protein Effect4
c.8331G>A [-] 5’SS Ex18 skipping (52%); CT (40.7%);
aberrant transcripts (7.3%)
r.[8331g>a,7977_8331del,?] p. [=; Y2660Ffs*43;?]
c.8331+1G>T [-] 5’SS Ex18 skipping (81%); Ex18-del157
(6.4%); ex17-del151+ex18 skipping
(6.1%); ivs17 58-nt retention+Ex18
skipping (3.7%);others (2.8%)
r.[7977_8331del,8175_8331del,7826_8331del,
7977_8331delins7976+1_7976+58]
p. [Y2660Ffs*43;W2725*;
G2609Dfs*4; Y2660Qfs*3]
c.8331+2T>C [-] 5’SS Ex18 skipping (87.1%); ex17-del151
+ex18 skipping (12.9%)
r.[7977_8331del,7826_8331del] p.[Y2660Ffs*43;
G2609Dfs*4]
1 Bold type variants indicate proposed causal or likely causal variants attending to the guidelines of the American College of Medical Genetics and
Genomics (see also S4 Table);
2 Affected motifs: 3’SS, 3’ splice site; 5’SS: 5’ splice site; Pyr, polypyrimidine tract; ESE, Exonic Splicing Enhancer; ESS, Exonic Splicing Silencer; [-]
disruption; [+] creation.
3 The proportion of each transcript is indicated between parentheses; CT: Canonical transcript.
4 HGVS nomenclature.
https://doi.org/10.1371/journal.pgen.1006691.t001
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skipping) [39], c.8023A>G (ex18-del309) [21] and c.8168A>G (partial ex18-del163) [40] dis-
played the same splicing patterns in patient RNA and minigene MGBR2_ex14-20, lending fur-
ther support to the reproducibility of minigene results. Furthermore, a recent splicing study of
30 variants of MLH1, MSH2, MSH6, and PMS2 genes (Lynch syndrome) showed that out-
comes of patient RNA and minigene assays were almost identical [41]. Thus, we can conclude
that the minigene strategy is sensitive and specific, so its use is suitable for the initial character-
ization of the splicing anomalies [21]. Nevertheless, it should be considered only as a support-
ive test rather than a confirmatory one since minigene results should be confirmed in patient
RNA or even at protein levels whenever possible. However, it is also worth mentioning that
splicing outcomes from patient RNA may be biased by technical limitations, physiological
alternative transcripts, and cell-type specific differences between the patient sample (princi-
pally leukocyte RNA) and the affected tissue [42].
Fig 3. Analysis of transcripts induced by DNA variants from exon 17. cDNA was amplified with primers
RTBR2_ex16-FW (BRCA2 exon 16) (blue peaks) and FAM-labelled RTpSAD-RV (vector exon V2) and
electrophoresed on a DNA sequencer with Genescan LIZ 1200 as size standard (orange/faint peaks). Arrows
indicate minor aberrant transcripts. Screenshots of electropherograms visualized with the Peak Scanner
software v1.0 are shown. Fragment sizes (bp) and relative fluorescent units are indicated on the x- and y-axes,
respectively.
https://doi.org/10.1371/journal.pgen.1006691.g003
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Fig 4. Analysis of transcripts induced by DNA variants from exon 18. cDNA was amplified with primers
RTBR2_ex16-FW (BRCA2 exon 16) (blue peaks) and FAM-labelled RTpSAD-RV (exon V2 of minigene) and
electrophoresed on a DNA sequencer with Genescan LIZ 1200 as size standard (orange/faint peaks). Arrows
indicate minor aberrant transcripts. Screenshots of electropherograms visualized with the Peak Scanner
software v1.0 are shown. Fragment sizes (bp) and relative fluorescent units are indicated on the x- and y-
axes, respectively. Electropherograms of c.8007A>G, c.8072C>T and c.8249_8250del are not represented
since they show similar patterns (partial exon 18 skipping) to other DNA variants (e.g. c.8009C>G).
https://doi.org/10.1371/journal.pgen.1006691.g004
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Finally, we have already cloned 43 out of the 50 exons of BRCA1/2 in the following 6 con-
structs: BRCA1 exons 2 to 10, and 12 to 23, BRCA2 exons 2 to 9, 9 to 10 (http://www.ibgm.
med.uva.es/servicios/servicio-de-splicing-minigenes/),14 to 20 (this study) and 19 to 27 [24].
Any variant of such exons can be easily tested with a straightforward protocol in less than two
weeks.
Fig 5. Schematic representation of splicing events and transcripts generated by wild type and mutant
minigenes. Exons and splicing reactions exons are represented by boxes and broken lines, respectively.
Anomalous/skipped exons and aberrant events are shown in red.
https://doi.org/10.1371/journal.pgen.1006691.g005
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Types of variants and splicing regulatory elements
Splicing is specifically regulated by a dense array of motifs and splicing factors so that an
important message of our study is that any nucleotide change has the potential of disrupting
this process. In fact, the 30 positive changes comprised 14 intronic and 16 exonic variants
including 11 missense, 1 frameshift, 1 nonsense and 3 synonymous predicted changes [43].
Synonymous variations are particularly interesting since they have traditionally been consid-
ered as neutral. Many sequence variations affect disease risk, including synonymous variants
that, actually, may have unexpected deleterious effects over the splicing and protein translation
mechanisms [44,45]. It has been shown that these variants account for 6–8% of all driver muta-
tions in oncogenes, where about half of them impair splicing [46]. Conversely, protein truncat-
ing variants (nonsense) are directly classified as deleterious though we have herein shown that
the associated-nucleotide changes can affect splicing regulatory elements, so we could observe
a “dangerous” unclassifiable splicing effect whenever they induced in-frame deletions of an
exon.
With regard to the affected splicing motifs of positive variants (Table 1, S2 Table) and tak-
ing into account the bioinformatics and splicing outcomes, we can conclude that 15 variants
affected the natural 5’ and 3’ splice sites, three the polypyrimidine tract, three created novel
alternative splice sites and 9 affected ESE/ESS motifs. The NNSplice, MaxEnt and HSF algo-
rithms accurately anticipated the splice site disruptions and the generation of novel active
sites, but the splicing outcomes were absolutely unpredictable reinforcing the current need of
functional assays. The characterization of the physiological alternative splicing events of
BRCA1 and BRCA2 [14,47] and improved computer tools will help to estimate the aberrant
transcripts that a particular DNA variant may generate. It is also worthy to mention that three
variants of the polypyrimidine tract, c.7806-9T>G, c.7977-7C>G and c.7977-6T>G, pro-
duced defective splicing. Pyrimidine to Purine changes at this element are critical for exon
recognition as we had previously described [25]. However, these modifications are barely iden-
tified by the splicing software with slight reductions of the splice site score (S2 Table). For
example, NNSplice of c.7806-9T>G calculated a weak decrease of the 3’ splice site score of
exon 17 from 0.95 to 0.83, yet it was associated with a total splicing disruption.
In silico predictions of ESE/ESS motifs, which are constituted by short-degenerate
sequences, showed low sensitivity. Nevertheless, there have been recently postulated two in sil-
ico approaches, ΔtESRseq and ΔHZEI, that accurately detect potential ESE-variants [43]. We
have found that 9 out of 28 pre-selected ESE/ESS variants affected splicing, so we have even
improved its accuracy with respect to former studies by virtue of the functional mapping by
microdeletions that has proven to be an exceptional method to refine ESE-variant selection.
This strategy revealed the presence of operating ESEs in intervals c.7944-7973 (exon 17) and
c.7979-8008 and c.8004-8033 (exon 18). Remarkably, 7 out of 9 ESE/ESS variants are placed
within these intervals of exon 18 confirming the value of preliminary ESE-mapping to choose
candidate variants and to fine map regulatory sequences. Interestingly, only the triple (c.7984,
c.8001 and c.8003) and double (c.8001 and c.8003) mutants of SF2 sites significantly affected
splicing whereas single mutants did not or did only weakly, suggesting a precise and com-
pound control of exon 18 processing, where ESE sequences might act cooperatively. In this
regard, while two possible SF2/ASF sites were bioinformatically predicted (c.7981_7987,
GATACGG, and c.8001_c.8007, CAGAAGA) (Fig 2C), preliminary siRNAs experiments sug-
gested the participation of the splicing factor SC35 in the regulation of exons 17 and 18 (S2
Fig), which is also involved in the regulation of a pathological GC site of the BTK gene [27].
Nevertheless, the definite identification of the splicing factors involved in exons 17 and 18 pro-
cessing should be carried out by further siRNA and pulldown assays [48]. Independently of
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the factors involved, these data allowed us to underline three small DNA segments (c.7944-
7973, c.7979-7988 and c.7999-8013) where spliceogenic ESE-variants may occur. Given the
poor precision of ESE/ESS-prediction software (12.2% of selected variants) [19,24], these data
will provide a very valuable information for genetic counselors with a view to selecting specific
exonic mutations within those intervals for splicing assays.
Donor-GC sites, such as that of exon 17, have been linked to alternative splicing [26] so that
they require the control by factors that promote their efficient selection [27]. Certainly, exons 17
and 18 undergo naturally-occurring alternative splicing producing minor transcripts Δ18 and
Δ17+18 [28], although in our study Δ18 was only detected at even lower levels in the wild type
minigene (<1%; S3 Table), together with the full-length transcript (99%). This may probably
be due to: i) the genomic context that influences exon recognition [15]; ii) tissue-dependent
alternative splicing as we used different host cells (MCF-7 vs. HeLa); and iii) RNA preparation
and storage conditions, primer design, PCR conditions, and PCR product detection methodol-
ogy can introduce small variations in splicing isoform ratios as previously reported [14,42].
Clinical interpretation of DNA variants
Identification of pathogenic variants with impact on splicing will aid in breast cancer predic-
tion, prevention and surveillance, but the clinical interpretation of the splicing outcomes of
candidate variants is a particularly complex task. It is accepted that a variant would be consid-
ered likely pathogenic when it causes a majority of aberrant RNA isoforms and generates a
stop codon or loss of a known functional domain. The identification of numerous anomalous
transcripts of exons 17 and 18 and the production of2 transcripts by many variants are
proofs of this arduous undertaking.
Twelve transcripts introduced a frameshift in the open reading frame and a PTC so they
inactivated BRCA2: ex17-del1, ex17del20, ex17ins8, ex17insAG, ex18 skipping, ex18-del191,
ex18-del298, ex18-del164, ex18-del157, ex18-del236, ex17-del151+ex18 skipping and
ivs17_58-nt retention+ex18 skipping. Conversely, exon 17 skipping, ex17-del69, ex18-ins6 and
ex18-del309 kept the reading frame with a priori unknown impact on BRCA2 function. Exon
17 skipping and ex17-del69 led to deletions of 57 and 23 amino acids, respectively, at the essen-
tial α-helical domain of the BRCA2 protein (amino acids 2479 to 2667). This domain facilitates
BRCA2 binding to single-stranded and double-stranded DNA [49]. Moreover, 30 out of the 57
residues encoded by exon 17 are strictly conserved from sea urchin to human revealing its
importance for BRCA2 activity (IARC BRCA2 alignment; http://agvgd.iarc.fr/BRCA2_Align.
htm). Likewise, it has been shown that the loss of exon 17 inactivates BRCA2 function [37]. Fur-
thermore, exon 17 variant c.7976G>A, which is associated with total exon 17 skipping, reached
odds of causality of>3,000:1 [38]. Consequently, we can infer that the rest of the variants with
ex17 skipping as the unique transcript, such as c.7976G>C and c.7976+1G>A, are also likely
pathogenic. Moreover, variants c.7806-9T>G and c.7806-2A>G with at least 3 abnormal tran-
scripts, including ex17 skipping, could also be considered as likely pathogenic, given that the
other transcripts disrupt the reading frame (Ivs16ins8 or ex17-del20) or leads to in-frame loss
of 23 aminoacids (ex17-del69), 13 of which are strictly conserved. The RNA isoform ex18-ins6
would insert new amino acids Ser-Phe between Tyr2658 and Arg2659. Precisely, amino acids
from Val2652 to Asp2661 are conserved from sea urchin, and two missense changes at this pro-
tein segment, p.Leu2653Pro and p.Arg2659Lys were formerly classified as deleterious [38,50].
Consequently, transcript ex18-ins6 might have a deleterious impact on BRCA2 function but it
is required further protein function studies. Finally, abnormal transcript ex18-del309 was pre-
dicted to cause an in-frame deletion of 103 amino acids between codons Ile2675 and Lys2777
of the OB1 (oligonucleotide ssDNA-binding fold) motif at the DNA binding domain of
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BRCA2, 24 of which are strictly conserved from sea urchin. Variant c.8023A>G, which induced
ex18del309, had previously been classified as pathogenic [21] (BIC and UMD databases), so
this transcript disrupts BRCA2 function. Also, c.8331G>A might be an important risk allele as
abnormal transcripts almost reach 60%, which is the suggested threshold for severe splicing
aberrations [51]. According to the guidelines of the American College of Medical Genetics and
Genomics (ACMG), [52] 12 spliceogenic variants were classified as pathogenic (c.7806-2A>G,
c.7806-1G>A, c.7806-1G>T, c.7806-1_7806-2dup, c.7976+1G>A, c.7977-3_7978del, c.7977-
2A>T, c.7977-1G>T, c.7977-1G>C, c.8009C>A, c.8331+1G>T and c.8331+2T>C) and 8
as likely pathogenic (c.7806-9T>G, c.7976G>C, c.7976G>A, c.7977-7C>G, c.7985C>G,
c.8023A>G, c.8035G>T and c.8331G>A), under the splicing viewpoint (S4 Table). Remark-
ably, all of them account for 72 independent records at the mutation databases (S4 Table) and
nine of them had been classified as VUS. Reclassification of VUS as deleterious will notably
increase the number of HBOC families who may benefit from tailored preventive and prophy-
lactic measures as well as new targeted therapies, such as Poly (ADP-ribose) polymerase
(PARP)-inhibitors, for patients with BRCA1/2 associated cancers [53].It is also worthy to men-
tion that causal and likely causal splicing variants account for a remarkable 30.8% (20/65) of all
predicted pathological variants of exons 17 and 18 at the BRCA2 Share database (S5 Table), rep-
resenting the second more frequent type of causal variants after frameshift mutations (44.6%).
On the other hand, two variants with weaker splicing alterations, c.8168A>G/ p.Asp2723Gly
(30%) and c.8249_8250del (7%), were previously classified as likely pathogenic (protein func-
tion and truncation, respectively) [38], so their pathogenicity may probably be due to a double
mechanism: protein inactivation and splicing disruption, like BRCA1 c.5123C>A (p.A1708E)
[25,54]. Likewise, c.8009C>A was previously classified as causal because of its predicted non-
sense change (p.Ser2670X), but it actually induces 96% of aberrant transcripts so it should be
reclassified as a spliceogenic variant. Reclassification of missense and protein truncation vari-
ants as splicing alterations might also have an effect in their penetrance and expressivity. Taken
together, 8 spliceogenic variants remain classified as VUS since relevant proportions of the
full-length transcript were detected (c.7975A>G, c.7977-6T>G, c.7988A>T, c.7992T>A,
c.8007A>G, c.8009C>T, c.8009C>G and c.8072C>T) (Table 1; S3 and S4 Tables). It is com-
plex to interpret the role of variants with partial splicing anomalies in HBOC under the clinical
perspective as they will require more studies to elucidate it. Nevertheless, we can speculate that
they represent low BC risk alleles that might interact with other susceptibility and protector
alleles to modify the overall BC risk. The incorporation of all these data into a single integrated
model of BC risk would improve disease prediction and prevention.
In conclusion, dysregulation of splicing should be considered as a primary mechanism of
gene inactivation to be investigated in human disease genes. Spliceogenic variants are compar-
atively abundant in BRCA2 exons 17 and 18 because recognition of both exons additionally
requires the regulation of specific ESE motifs in exons 17 and 18, whose abolitions drive splic-
ing aberrations. Furthermore, the pSAD-based minigenes are useful tools for molecular diag-
nostics and genetic counseling of hereditary breast/ovarian cancer or other genetic disorders
as well as for the basic research on the splicing process. Hence, RNA assays supply essential
information for the clinical interpretation of variants that should be incorporated in the
genetic counselling of human hereditary diseases.
Materials and methods
Databases and bioinformatics analyses
BRCA2 variants of breast/ovarian cancer patients were available from the BIC (https://
research.nhgri.nih.gov/projects/bic/Member/index.shtml) and the BRCA Share databases (last
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accessed date 2016/04/01; http://www.umd.be/BRCA2/) [55]. Variants of intron 17 were
collected from the 1000 Genomes database (http://browser.1000genomes.org/Homo_
sapiens/Gene/Summary?db=core;g=ENSG00000139618;r=13:32889611-32973805;t=
ENST00000380152). Variant descriptions were according to the BRCA2 GenBank sequence
NM000059.1 and the guidelines of the Human Genome Variation Society (HGVS; http://
www.hgvs.org/mutnomen/).
Mutant and wild type (wt) sequences were analyzed with NNSPLICE (http://www.fruitfly.
org/seq_tools/splice.html) [56], and Human Splicing Finder version 3.0 (HSF; http://www.
umd.be/HSF3/)[57], which includes algorithms for splice sites, silencers and enhancers
[31,58–62].
Minigene construction
MGBR2_ex14-20 was assembled in four steps by overlapping extension PCR or classical
restriction digestion/ligation cloning with three intermediate constructs: MGBR2EX17-18,
MGBR2EX16-18, and MGBR2EX16-20. All the inserts were amplified with Phusion High
Fidelity polymerase (Thermo Fisher Scientific, Waltham, MA, USA) and primers indicated on
S1 Table. Exons 17–18 were subcloned into the pSAD vector by overlapping extension PCR.
Then, exon 16 was added by the same technique. Exons 19–20 were inserted between the Xhol
and BamHI restriction sites of the 16–18 construct. Finally, exons 14–15 were introduced
using the EagI and SacI restriction sites. All clones were functionally checked in MCF-7 cells.
Site-directed mutagenesis
DNA variants were introduced with the QuikChange Lightning kit (Agilent, Santa Clara, CA).
The wt minigene MGBR2_ex14-20 was used as template to generate 52 BIC/BRCA Share
DNA variants as well as seventeen exonic (17 and 18) and four intronic (ivs17) microdeletions
(S2 Table). The first two and the last three nucleotides of each exon were always preserved to
avoid any disruptions of the canonical acceptor and donor sites, respectively. Deletions were
introduced by PCR-mutagenesis with chimeric 50-60mer primers containing 25–30 nucleo-
tides of each end of the deletion.
Transfection of eukaryotic cells
Approximately 2x105 MCF7 cells were grown to 90% confluency in 0.5 mL of medium
(MEME, 10% Fetal Bovine Serum, 2 mM glutamine, 1% Non-essential amino acids and 1%
Penicillin/Streptomycin) in 4-well plates (Nunc, Roskilde, Denmark). Cells were transiently
transfected with 1 μg of each minigene and 2 μL of Lipofectamine 2000 or low toxicity Lipofec-
tamine (Life Technologies, Carlsbad, CA). To inhibit nonsense mediated decay (NMD), cells
were incubated with cycloheximide (Sigma-Aldrich, St. Louis, MO) 300 μg/mL for 4 hours.
RNA was purified with the Genematrix Universal RNA Purification Kit (EURx, Gdansk,
Poland) with on-column DNAse I digestion to degrade genomic DNA that could interfere in
RT-PCR.
RT-PCR of minigenes
Retrotranscription was carried out with 400 ng of RNA and RevertAid H Minus First Strand
cDNA Synthesis Kit (Life Technologies), using gene specific primer RTPSPL3-RV (5’TGAG
GAGTGAATTGGTCGAA 3’). Samples were incubated at 42˚C for 1 hour, and reactions
were inactivated at 70˚C for 5 min. Then, 1–2 μl of the resultant cDNA were amplified
with SD6-PSPL3_RTFW (5’-TCACCTGGACAACCTCAAAG-3’) or RTBR2_ex16FW
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(5’-TATGGACTGGAAAAGGAATAC-3’) and RTpSAD-RV (Patent P201231427, CSIC)
(sizes: 1012 and 1806 bp, respectively) using Platinum Taq DNA polymerase (Life Technolo-
gies). Samples were denatured at 94˚C for 2 min, followed by 35 cycles consisting of 94˚C for
30 sec, 59˚C for 30 sec, and 72˚C (1 min/kb), and a final extension step at 72˚C for 5 min.
Sequencing reactions were performed either using the kit BigDye Terminator v3.1 Cycle
Sequencing Kit (Applied Biosystems) following the manufacturer’s instructions or by the
sequencing facility of Macrogen Europe (Amsterdam, The Netherlands). All transcripts from
exon 18 microdeletion c.8004_8013del were subcloned into the pJet1.2 PCR cloning vector
(Thermo Fisher Scientific) and sequenced.
In order to quantify all transcripts, semi-quantitative fluorescent PCRs were undertaken at
least in triplicate (>234 assays were performed of 52 natural plus 26 artificial mutants; S2
Table) with primers RTBR2_ex16-FW and FAM-RTpSAD-RV and Platinum Taq DNA poly-
merase (Life Technologies) under standard conditions except that 26 cycles were herein
applied [19,63]. FAM-labeled products were run with LIZ-1200 Size Standard at the Macrogen
facility and analyzed with the Peak Scanner software V1.0. Only peaks with heights 50 RFU
(Relative Fluorescence Units) were taken into account. Peak areas were used to quantify the
relative abundance of each transcript that was the average of at least three experiments [19].
Supporting information
S1 Table. Primers used for the construction of the MGBR2_ex14-20 minigene.
(PDF)
S2 Table. Bioinformatics analysis and mutagenesis primers of selected reported and artifi-
cial DNA variants of exons 17 and 18.
(DOCX)
S3 Table. Relative quantification of transcripts induced by DNA variants and microdele-
tions of BRCA2 exons 17and 18 in MCF-7 cells.
(PDF)
S4 Table. Analysis of the 52 assayed variants according to the guidelines of the American
College of Medical Genetics and Genomics (ACMG).
(PDF)
S5 Table. Distribution of pathogenic/likely pathogenic variants by type according to the
BRCA Share database and this study.
(PDF)
S1 Fig. Capillary electrophoresis of the [FAM]-RT-PCR products generated by the mutant
c.7976+2C>T (canonical donor GT site, above) and the wild type (below) minigenes. The
blue peaks denote the full-length transcripts induced by both minigenes and the Genescan
1200 Size Standard (Applied Biosystems) is shown as orange peaks.
(TIF)
S2 Fig. Impact of RNA interference-mediated depletion of splicing factors SC35, SF2/ASF
and Tra2β on splicing of minigene MGBR2_ex14-20. About 1.5x105 MCF7 cells were sub-
jected to a two-hit transfection with Oligofectamine (Thermo Fisher Scientific) and custom-
made small interfering RNA (siRNA) at a final concentration of 0.08μM on day 2, the mini-
gene was transfected with Lipofectamine (Thermo Fisher Scientific) on day 4, and RNA was
extracted on day 5. The following siRNAs were used: SC35 (aauccaggucgcgaucgaa), SF2/ASF
(acgauugccgcaucuacgu), Tra2β (ggaucuucgugaaguauuu) and a control luciferase siRNA.
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RT-PCR products were run on an agarose gel (1.0%) and stained with Ethidium Bromide. Sev-
eral aberrant transcripts are visualized, some of which are indicated by arrows.
(TIF)
S3 Fig. High resolution of capillary electrophoresis of fluorescent RT-PCRs. Electrophero-
grams of the wild type minigene and mutations c.7806-1G>A and c.7806-1_7806-2dup were
overlaid. Transcripts ex17-del1 and ex17-insAG differed in size by only 1 and 2 nucleotides,
respectively, from the canonical transcript despite the large size (1,012 nt) of the RT-PCR
products. The Liz-1200 size standard is shown as orange peaks.
(TIF)
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